<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Euro Surveill</journal-id><journal-id journal-id-type="iso-abbrev">Euro Surveill</journal-id><journal-id journal-id-type="publisher-id">eurosurveillance</journal-id><journal-title-group><journal-title>Eurosurveillance</journal-title></journal-title-group><issn pub-type="ppub">1025-496X</issn><issn pub-type="epub">1560-7917</issn><publisher><publisher-name>European Centre for Disease Prevention and Control (ECDC)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16-00728</article-id><article-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.39.16-00728</article-id><article-id pub-id-type="publisher-id">16-00728</article-id><article-categories><subj-group subj-group-type="heading"><subject>Surveillance and Outbreak Report</subject></subj-group></article-categories><title-group><article-title>Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016</article-title><alt-title alt-title-type="right-running"><ext-link ext-link-type="uri" xlink:href="http://www.eurosurveillance.org">www.eurosurveillance.org</ext-link> &#x02013; Ehlkes et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ehlkes</surname><given-names>Lutz</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Samosny</surname><given-names>Gerhard</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Burckhardt</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vogt</surname><given-names>Manfred</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bent</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jahn</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zanger</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><aff id="aff1">
<label>1</label>Federal State Agency for Consumer &#x00026; Health Protection Rhineland-Palatinate, Koblenz, Germany</aff><aff id="aff2">
<label>2</label>Postgraduate Training for Applied Epidemiology (PAE), Robert Koch Institute (RKI), Berlin, Germany</aff><aff id="aff3">
<label>3</label>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</aff><aff id="aff4">
<label>4</label>These authors contributed equally to this article and share first authorship</aff><aff id="aff5">
<label>5</label>Health Department Alzey-Worms, Alzey, Germany</aff><aff id="aff6">
<label>6</label>Federal State Ministry for Social Affairs, Employment, Health, and Demographics Rhineland-Palatinate, Mainz, Germany</aff><aff id="aff7">
<label>7</label>Institute of Public Health, University Hospitals, Heidelberg, Germany</aff><aff id="aff8">
<label>8</label>Department of Infectious Diseases, Medical Microbiology and Hygiene, University Hospitals, Heidelberg, Germany</aff></contrib-group><author-notes><fn id="afn1"><p>Correspondence: Philipp Zanger (<email xlink:href="philipp.zanger@lua.rlp.de">philipp.zanger@lua.rlp.de</email>)</p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>9</month><year>2017</year></pub-date><volume>22</volume><issue>39</issue><elocation-id>16-00728</elocation-id><history><date date-type="received"><day>04</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>01</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>This article is copyright of The Authors, 2017.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Due to rapid diagnosis and isolation of imported cases, community outbreaks of viral haemorrhagic fevers (VHF) are considered unlikely in industrialised countries. In March 2016, the first documented locally acquired case of Lassa fever (LF) outside Africa occurred, demonstrating the disease&#x02019;s potential as a cross-border health threat. We describe the management surrounding this case of LF in Rhineland-Palatinate &#x02013; the German federal state where secondary transmission occurred. Twelve days after having been exposed to the corpse of a LF case imported from Togo, a symptomatic undertaker tested positive for Lassa virus RNA. Potential contacts were traced, categorised based on exposure risk, and monitored. Overall, we identified 21 contact persons with legal residency in Rhineland-Palatinate: seven related to the index case, 13 to the secondary case, and one related to both. The secondary case received treatment and recovered. Five contacts were quarantined and one was temporarily banned from work. No further transmission occurred. Based on the experience gained during the outbreak and a review of national and international guidelines, we conclude that exposure risk attributable to corpses may currently be underestimated, and we present suggestions that may help to improve the anti-epidemic response to imported VHF cases in industrialised countries.</p></abstract><kwd-group><title>Keywords: </title><kwd>disease outbreaks</kwd><kwd>disease transmission, infectious</kwd><kwd>hemorrhagic fevers, viral</kwd><kwd>communicable diseases, emerging</kwd><kwd>disease transmission</kwd><kwd>epidemiology</kwd><kwd>contact tracing</kwd><kwd>Arenaviridae</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>sequence</meta-name><meta-value>5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>On 25 February 2016, a healthcare professional with a rapidly deteriorating health condition, was evacuated from Togo to Cologne, North Rhine-Westphalia, Germany, where he died of multiple organ failure within hours of hospital admission [<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]. After an autopsy [<xref rid="r3" ref-type="bibr">3</xref>], the corpse was released from the hospital and transferred to a mortuary in Rhineland-Palatinate, where he was meant to be embalmed before repatriation to Togo. Six days after releasing the corpse, tissue samples that had been sent to the World Health Organization (WHO) Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research at the Bernhard Nocht-Institute for Tropical Medicine in Hamburg for further diagnostics tested positive for Lassa virus (LASV) [<xref rid="r1" ref-type="bibr">1</xref>]. As a result, contact tracing was initiated in all federal states of Germany where individuals might have been in contact with the patient while he was still alive or with his corpse.</p><p>Lassa fever (LF) is a viral haemorrhagic fever (VHF) caused by Lassa virus (LASV) &#x02013; an enveloped, single stranded RNA virus belonging to the family of Arenaviridae. The incubation period ranges from 3 to 21 days [<xref rid="r4" ref-type="bibr">4</xref>]. Disease onset is characterised by unspecific, influenza-like symptoms. Signs of increased vascular permeability, such as haemorrhages, oedema, and shock, indicate severe LF [<xref rid="r5" ref-type="bibr">5</xref>]. Symptomatic treatment of LF comprises fluid replacement and antipyretic drugs. Intensive care is required for the management of severe LF. The nucleosid-analogon ribavirin inhibits viral replication and its early administration was shown to improve survival of patients with LF [<xref rid="r6" ref-type="bibr">6</xref>]. Its prophylactic use may be considered after exposure with high or very high risk of infection [<xref rid="r7" ref-type="bibr">7</xref>]. Due to the high proportion of inapparent and mildly symptomatic infections, overall mortality of LASV infection is ca 1%, but increases to 18&#x02013;31% for cases that require hospital care [<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r9" ref-type="bibr">9</xref>]. There is currently no vaccine to prevent LV infection.</p><p>LASV is endemic in West Africa [<xref rid="r10" ref-type="bibr">10</xref>]. It is mainly transmitted via excretions of rodents, either by direct contact with the mucosae or breached skin, ingestion of contaminated food, or inhalation of contaminated dust. Its natural hosts are multimammate rats (<italic>Mastomys natalensis</italic>), which do not develop symptoms, but can excrete the virus for an extended period of time. In endemic regions, reported LASV seroprevalences in rodents range from 5% to 45% [<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]. Distribution of the natural host is a strong determinant of LASV endemicity [<xref rid="r10" ref-type="bibr">10</xref>]. To date, human cases of LF have been reported from Benin, Burkina Faso, C&#x000f4;te d&#x02019;Ivoire, Ghana, Guinea, Liberia, Mali, Nigeria, and Sierra Leone [<xref rid="r10" ref-type="bibr">10</xref>], where the population prevalence of LASV-specific IgG antibodies ranges from 14% to 44% [<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]. Community outbreaks of LF are mainly fuelled by zoonotic transmission. For nosocomial outbreaks however, person-to-person transmission of LASV via bodily fluids is particularly relevant [<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>], and super-spreading events have been described [<xref rid="r16" ref-type="bibr">16</xref>].</p><p>Importations of LF cases to industrialised countries are generally rare, but could become a more common cross-border health threat considering increased connectivity to endemic countries. Although imported LF cases through international travel and repatriation have been reported from &#x02013; among others - Germany, the United Kingdom (UK), and the United States (US) [<xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r21" ref-type="bibr">21</xref>], there has been no report of secondary cases following the import to non-endemic parts of the world.</p><p>The Ebola virus disease (EVD) epidemic struck West Africa in 2014, and imported cases were reported from various industrialised countries. This illustrated the need for VHF outbreak management capacity to an unprecedented extent. The subsequent activities to scale up preparedness led to the compilation of various EVD outbreak management guidelines in Europe [<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r25" ref-type="bibr">25</xref>].</p><p>In Germany, there are two documents addressing the outbreak management of VHF: recommendations covering the outbreak management of VHF in general (published in 2001) [<xref rid="r26" ref-type="bibr">26</xref>], and another document addressing EVD in particular (triggered by the outbreak in West Africa and issued in March 2016) [<xref rid="r22" ref-type="bibr">22</xref>]. Both provide guidance and best practices with regard to diagnostics, treatment in dedicated facilities, biosafety, waste disposal, disinfection, logistics, contact tracing, risk classification, control measures, and post-process evaluation.</p><p>Here we describe the events surrounding a locally acquired case of LF outside of Africa and report the challenges we faced with regard to contact tracing and enforcement of control measures in the federal state of Rhineland-Palatinate. We then review national and international VHF guidelines to identify complementary information of value for managing VHF outbreaks in the respective setting. We also present suggestions that may help improve the anti-epidemic management of imported cases of VHF in Germany and Europe.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Contact tracing, exposure risk classification and management</title><p>Upon information about the laboratory confirmation of LV in the index case, we contacted the embalming contractor, on whose premises the corpse of the index case (IC) was stored, and asked for a list of employees and everyone else who could have been in contact with the corpse. We then followed up all potentially exposed individuals. For rapid initial assessment and due to time constraints, we conducted ad hoc interviews by phone, using a short standardised questionnaire to estimate the individual extent of exposure. Individuals reporting or suspecting having had contact to the corpse, to a potential symptomatic case, or to their bodily fluids, were considered contact persons and classified into risk categories according to the German VHF recommendations ([<xref rid="r26" ref-type="bibr">26</xref>], <xref ref-type="boxed-text" rid="b1">Box</xref>). We used the day of first exposure plus the minimum incubation period of 3 days as the earliest time point to produce secondary cases, in case symptom onset of a LF case and thus the beginning of the period of infectiousness could not be clearly discerned.</p><boxed-text id="b1" position="float" orientation="portrait"><label>Box</label><caption><title>Exposure risk classification of contacts to VHF cases, used in the Lassa fever outbreak in Rhineland-Palatinate, Germany, 2016<sup>a</sup>
</title></caption><p>
<bold>Very high risk (Category Ia)</bold>
</p><p>&#x02022; Subcutaneous contact <italic>or</italic> contact of a mucous membrane to bodily fluids <italic>or</italic> tissue of a VHF patient</p><p>
<bold>High risk (Category Ib)</bold>
</p><p>&#x02022; Contact (skin or aerosol) to infectious bodily fluids/tissue of a VHF patient</p><p>&#x02022; Contact to infectious bodily fluids/tissue/carcass of a VHF-positive animal</p><p>
<bold>Medium risk (Category II)</bold>
</p><p>&#x02022; Providing care to or handling diagnostic samples of a VHF patient</p><p>&#x02022; Direct contact to potentially contaminated objects of a VHF patient</p><p>&#x02022; Direct contact to the corpse of confirmed or suspected VHF case</p><p>&#x02022; Contact to VHF-positive animal</p><p>&#x02022; Close proximity to a symptomatic VHF case, e.g. during flight</p><p>
<bold>Low risk (Category III)</bold>
</p><p>&#x02022; Any other contact to a confirmed VHF case (e.g. in same room with VHF case)</p><p>&#x02022; Contact of medical staff to confirmed case using proper personal protective equipment (including respirators)</p><fn-group><fn><p>VHF: viral haemorrhagic fever.</p></fn><fn><p>
<sup>a</sup> Translated from Fock et al. [<xref rid="r26" ref-type="bibr">26</xref>].</p></fn></fn-group></boxed-text><p>We initiated passive symptom monitoring of all contacts in the risk categories I-III. We asked them to report their body temperature and the occurrence of any symptoms by email or telephone every 12 hours for the maximum incubation period of 21 days post-exposure to the LF case. Depending on the assigned risk category, enhanced control measures were enforced (<xref ref-type="table" rid="t1">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Control measures for contacts of viral haemorrhagic fever cases, as used during the Lassa fever outbreak in Rhineland-Palatinate, Germany, 2016<sup>a</sup>
</title></caption><table frame="hsides" rules="groups"><col width="32.16%" span="1"/><col width="11.09%" span="1"/><col width="6.55%" span="1"/><col width="10.13%" span="1"/><col width="6.15%" span="1"/><col width="11.09%" span="1"/><col width="6.55%" span="1"/><col width="10.13%" span="1"/><col width="6.15%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-top: solid 1pt; border-bottom: solid 1pt" colspan="1">Exposure risk /Control measure</th><th valign="middle" colspan="4" align="left" scope="colgroup" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1">Contact is asymptomatic</th><th valign="middle" colspan="4" align="left" scope="colgroup" style="border-top: solid 1pt; border-bottom: solid 1pt" rowspan="1">Contact is symptomatic</th></tr><tr><th valign="middle" colspan="1" align="left" scope="colgroup" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1">Very&#x000a0;high<break/>Ia</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">High<break/>Ib</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">Medium<break/>II</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">Low<break/>III</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">Very&#x000a0;high<break/>Ia</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">High<break/>Ib</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">Medium<break/>II</th><th valign="middle" align="left" scope="col" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">Low<break/>III</th></tr></thead><tbody><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">
<bold>Symptom monitoring</bold>
</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td></tr><tr><td valign="middle" align="left" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" scope="row" rowspan="1" colspan="1">
<bold>Home quarantine</bold>
</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">
<bold>Quarantine/isolation in hospital</bold>
</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;*</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">*</td></tr><tr><td valign="middle" align="left" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" scope="row" rowspan="1" colspan="1">
<bold>Post exposure prophylaxis</bold>
</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">
<bold>Blood sample at baseline<sup>b</sup></bold>
</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">NA</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">NA</td></tr><tr><td valign="middle" align="left" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" scope="row" rowspan="1" colspan="1">
<bold>PCR diagnostics for LASV</bold>
</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">
<bold>Temporary work ban, high risk professions<sup>c</sup></bold>
</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x02009;+</td></tr><tr><td valign="middle" align="left" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" scope="row" rowspan="1" colspan="1">
<bold>Temporary work ban, any profession</bold>
</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">-</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">&#x02009;+</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td><td valign="middle" align="center" style="border-top: solid 0.50pt; border-bottom: solid 0.50pt; background-color:rgb(192,192,192)" rowspan="1" colspan="1">*</td></tr></tbody></table><table-wrap-foot><p>&#x02009;+:&#x02009;measure is recommended; -:&#x02009;measure is not recommended; *:&#x02009;measure to be considered on individual basis; LASV:&#x02009;Lassa virus; NA:&#x02009;not applicable.</p><p>
<sup>a</sup> Measures based on reference [<xref rid="r26" ref-type="bibr">26</xref>].</p><p>
<sup>b</sup> For diagnostic testing, in case symptoms develop or disease progresses.</p><p>
<sup>c</sup> Professions with close physical contact to people (hospitals, schools, etc.); subject to individual decision.</p></table-wrap-foot></table-wrap><p>Measures included 21 days of active symptom monitoring, temporary work ban, home/hospital quarantine, and/or isolation, post exposure. Other measures included PCR-diagnostics and post-exposure prophylaxis with ribavirin. For contacts who developed suspicious symptoms, a more cautious set of measures was applied. In some instances, this required individual review and decision making by a panel of experts in infectious diseases and public health.</p><p>After the first assessment, we conducted in-depth interviews of ca 30 minutes each, using a more qualitative approach with open questions. We started with contacts for whom initial underestimation of exposure risk was suspected, based on inconsistencies or missing information when triangulating information gathered during the ad hoc assessment. The interviewees were talked through the exposure incident and asked to describe the exact type and proximity of contact. The purpose of these interviews was to fill information gaps, clear inconsistencies, and identify further contact persons, but also to discuss the possibility for unconscious exposure, such as touching potentially contaminated surfaces or material. Based on our in-depth interviews, we re-assessed initial risk classifications and respective control measures (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Results of exposure risk categorisation based on ad hoc compared with in-depth interviews with contacts from a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016</title></caption><table frame="hsides" rules="groups"><col width="14.18%" span="1"/><col width="29.35%" span="1"/><col width="9.35%" span="1"/><col width="37.77%" span="1"/><col width="9.35%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" colspan="1">&#x000a0;&#x000a0;Contacts</th><th colspan="2" valign="top" align="center" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1">&#x000a0;&#x000a0;Ad hoc interview</th><th colspan="2" valign="top" align="center" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1">&#x000a0;&#x000a0;In-depth interview / triangulation</th></tr><tr><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1">&#x000a0;&#x000a0;Type of contact</th><th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Risk category<sup>a</sup>
</th><th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Issues raised during reassessment</th><th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Risk category<sup>a</sup>
</th></tr></thead><tbody><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Index case</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Nurse evacuated from Togo, died in Cologne, transferred to mortuary in Rhineland-Palatinate</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;NA</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;NA</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;NA</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contact 1 / secondary&#x000a0;case</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Handled corpse of IC with double gloving, no facial mask, no apron</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Autopsied corpse of IC that was losing massive amounts of fluid; potential contact to contaminated surfaces or objects after ungloving</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contact 2</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;In same room as IC but no direct contact; work-related contact to C1</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Potential contact to contaminated surfaces (door handle, sink) in room where C1 handled IC</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contacts 3&#x02013;8</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Team transporting corpse of IC to crematory; full personal protective equipment (BSL-4 equivalent)</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;No safety breach reported (upon probing)</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contacts 9&#x02013;12</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Potential exposure to bodily fluids of C1</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Ib</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;No additional information obtained</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Ib</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contact 13</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Travelling in a car with C1</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;No contact to corpse or potentially contaminated surfaces; no direct contact to C1</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contacts 14&#x02013;18</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Visitors to C1</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;No additional information obtained</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;III</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Contacts 19&#x02013;21</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;C19 physical contact to C1 without personal protective equipment</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;Interviews with C19 led to identification of C20 and C21; had contact to C1 at onset of symptoms</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">&#x000a0;&#x000a0;II</td></tr></tbody></table><table-wrap-foot><p>BSL: biosafety level; C:&#x02009;contact; IC:&#x02009;index case; NA: not applicable.</p><p>
<sup>a</sup> According to viral haemorrhagic fever recommendations [<xref rid="r26" ref-type="bibr">26</xref>].</p></table-wrap-foot></table-wrap></sec><sec><title>Symptom monitoring and control measures</title><p>We enforced control measures according to German VHF recommendations [<xref rid="r26" ref-type="bibr">26</xref>] (<xref ref-type="table" rid="t1">Table 1</xref>). However, these do not explicitly specify which symptoms other than fever justify a more cautious set of measures. Therefore, we added other symptoms of interest as sore throat, rhinitis, headache, cough, other respiratory symptoms, mucosal bleeding, myalgia, arthralgia, and gastro-intestinal symptoms. We defined fever as oral, rectal, or tympanal body temperature&#x02009;&#x02265;&#x02009;38.0&#x02009;&#x000b0;C. The assessment of contacts was complicated by the seasonally high prevalence of influenza-like illnesses in March that lowered the already limited specificity of symptoms used to indicate potential LF. Therefore, in low risk contacts (III), we defined either fever or a reported progression in the intensity of non-febrile influenza-like symptoms (i.e. sore throat, headache, cough and/or rhinitis) over 4 days as the trigger for additional measures. Contacts with high or medium exposure risk (I-II), by contrast, were subject to enhanced measures, regardless of symptom progression, as soon as any of the above mentioned symptoms occurred. If indicated, genome level-informed [<xref rid="r27" ref-type="bibr">27</xref>] reverse transcriptase quantitative PCR from blood was performed at the biosafety level (BSL) 4 laboratory at the Institute of Virology, University of Marburg, to confirm LASV infection.</p></sec><sec><title>Review of existing VHF guidelines</title><p>We searched governmental, European Union (EU), and WHO online resources for publicly accessible English and German language VHF/EVD guidelines of relevance for contact tracing and management in Europe. We reviewed the respective outbreak management sections for particular strengths and common gaps, and highlighted key points with potential benefit for the outbreak management following imported VHF cases.</p></sec><sec><title>Ethical considerations</title><p>The events around this first LF outbreak outside Africa received wide media coverage. All details of identifiable subjects described in this work have been previously released into the public domain [<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>].</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Contact tracing, exposure risk classification and management</title><p>The autopsy results were not available until 6 days after the arrival of the corpse at the mortuary. By the time the PCR-positive test result was communicated, the embalmment had not yet been performed. However, two employees of the mortuary had potentially been exposed to infectious material. One contact (C1), an undertaker using double gloving but no facial protection and apron when handling the corpse, was classified as a risk category III contact in the initial rapid assessment. However, during the in-depth interviews we learned that the autopsied corpse had started to decompose and had lost large amounts of fluid when being handled. Talking C1 through this setting again, direct contact to bodily fluids could be excluded. However, considerable uncertainty about contact to contaminated surfaces after ungloving remained. Therefore, we re-classified C1 into risk category II (<xref ref-type="table" rid="t2">Table 2</xref>). The other contact (C2) was present in the same room as C1, but had no contact to the corpse (risk category III). Later during the outbreak investigation, similar doubts about having touched potentially contaminated surfaces as in the case of C1 arose. Hence, we also re-classified C2 from risk category III into II.</p><p>Two days after discovering the index case was LASV-positive, his corpse was transferred for cremation by a team in full personal protective equipment (BSL&#x000a0;4 equivalent). We classified them as risk category III contacts (C3&#x02013;8) according to the VHF recommendations [<xref rid="r26" ref-type="bibr">26</xref>].</p><p>At the time of exposure to the corpse of the index case, C1 was recovering from an upper respiratory tract infection [<xref rid="r1" ref-type="bibr">1</xref>]. His condition worsened 4 days after handling the corpse. On day 6 post exposure, the LASV-positive test result of the index case was communicated to the health authorities. Being in risk category II, this warranted a home quarantine (from day 7 post exposure, onwards) and PCR-testing for LASV, although C1 had no fever at the time. On day 8 post exposure, the negative PCR test result of C1 was communicated. As symptoms of C1 still persisted, a second blood sample was taken. This tested PCR-positive for LASV on day 12 post exposure [<xref rid="r27" ref-type="bibr">27</xref>]. On the same day, the health status of C1 deteriorated and he was transferred to the isolation ward of Frankfurt University Hospital for treatment with ribavirin [<xref rid="r29" ref-type="bibr">29</xref>]. The patient fully recovered after 21 days in isolation.</p><p>At the time C1 tested positive for LASV, his deteriorating health justified the classification of those with likely exposure to his bodily fluids (C9-C12) into risk category Ib. We identified seven additional contacts to the secondary case, of which six (C13-C18) were classified into risk category III, and one (C19) into risk category II. Futhermore, in-depth interviews allowed us to trace two further contacts of C1, unnoticed previously (C20&#x02009;and&#x02009;C21, both risk category II).</p><p>In total, we identified 21 contact persons with legal residency in Rhineland-Palatinate, Germany (<xref ref-type="table" rid="t2">Table 2</xref>): seven with contact only to the IC, 13 with contact only to the secondary case, and one contact with exposure to both cases. Compliance of all contacts during follow-up was high and we had no loss to follow-up. No further transmission occurred and the outbreak was declared over on 6 April 2016.</p></sec><sec><title>Symptom monitoring and control measures</title><p>In total, nine contacts developed non-febrile influenza-like symptoms, particularly cough, rhinitis, and/or sore throat. Six of them were high or medium risk contacts (category Ib/II), and underwent PCR testing for LASV with negative results. High risk contacts (category Ib) were quarantined, offered post-exposure prophylaxis with ribavirin, and discharged 21 days post exposure. One medium risk contact (category II) was quarantined at home and one was subject to a temporary work ban. The three low risk contacts (category III) were closely monitored, but did not show any progression to more severe symptoms. Hence, neither PCR-testing nor additional control measures were enforced. A timeline of the outbreak is provided in the <xref ref-type="fig" rid="f1">Figure</xref>.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure</label><caption><p>Timeline of events related to the Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016</p></caption><p content-type="fig-fn">C:&#x02009;contact number; IC:&#x02009;index case; LASV:&#x02009;Lassa virus; SC: secondary case; RP: Rhineland-Palatinate.</p><p content-type="fig-fn">Contact incidents before the minimum incubation period of 3 days are ignored.</p><graphic xlink:href="16-00728-f1"/></fig></sec><sec><title>Review of existing VHF guidelines</title><p>In addition to the German VHF recommendations [<xref rid="r26" ref-type="bibr">26</xref>] used in the outbreak described here, we identified five guidelines of relevance: one concerning the management of VHF (UK) [<xref rid="r30" ref-type="bibr">30</xref>], and four concerning the management of EVD (Germany, European Centre for Disease Prevention and Control (ECDC), US Centers for Disease Control and Prevention (CDC) / WHO, and UK) [<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r25" ref-type="bibr">25</xref>]. Their approach is similar; first, an assessment of the exposure risk of suspected contacts is conducted. On the basis of the respective risk category and symptoms, control measures are enforced. In the context of the outbreak reported here, the review identified particular strengths but also gaps, which may be addressed in harmonised European guidelines for the management of VHF outbreaks in the future (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Strengths in VHF/EVD management guidelines relevant to Europe, 2016</title></caption><table frame="hsides" rules="groups"><col width="23.89%" span="1"/><col width="56.55%" span="1"/><col width="19.56%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Area of guidance</th><th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Strength</th><th valign="middle" align="center" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Example</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Trigger for control measures</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Comprehensive set of unambiguously defined symptoms, which allows taking reproducible decisions in favour of or against enforcing enhanced control measures</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r24" ref-type="bibr">24</xref>]</td></tr><tr><td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Exposure risk classification</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Classify exposure to corpses of individuals who died of VHF, as high-risk</td><td valign="middle" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Personal protective equipment</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Detailed description of the level of personal protective equipment required to decrease exposure risk</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Interviewing contact persons</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Guidance and suggestions on how to conduct interviews</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r24" ref-type="bibr">24</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Sexual&#x000a0;transmission</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Explicit mention of sexual transmission as an exposure risk (even after recovery) and how it can be avoided</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>-<xref rid="r25" ref-type="bibr">25</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Travel of contact persons</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Explicit mention of travel restrictions as a control measure for contacts</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>,<xref rid="r25" ref-type="bibr">25</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Waste management</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Instructions for waste disposal and disinfection measures</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r30" ref-type="bibr">30</xref>]</td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Information&#x000a0;materials</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Provision of template information sheet for contact persons</td><td valign="top" align="center" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><p>EVD: Ebola virus disease; NA: not available; VHF: viral haemorrhagic fevers.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In 2014, the EVD epidemic quickly spread across borders and continents. As a result, most countries, including Germany, scaled up their EVD preparedness with a focus on timely detection of imported cases, as well as their isolation and treatment at designated facilities. This approach is considered most feasible and effective in preventing outbreaks, as detection of imported cases is expected before person-to-person transmission occurs.</p><p>Here we presented the first secondary case of LF outside Africa, occurring in an undertaker in Rhineland-Palatinate, after he came into contact with an autopsied corpse of a patient that had died from LF in Cologne, North Rhine-Westphalia, Germany. The abscence of similar cases and only one single published report of a physician seroconverting upon contact to a LF case [<xref rid="r21" ref-type="bibr">21</xref>] suggests that the overall risk of LF outbreaks triggered by imported cases is very low. Nevertheless, these observations illustrate that LASV transmission in the community and consecutive outbreak management in industrialised countries can become a realistic scenario. Being legally in charge of tracing contacts with residency in Rhineland-Palatinate, we faced a number of challenges that may also apply to similar settings in other countries, where VHF outbreaks in the community are currently an underestimated threat.</p><p>In outbreak situations, particularly those involving VHF, prioritisation of tasks and adequate time allocation are paramount. Ad hoc interviews allow an initial rapid assessment and provide an overview regarding the magnitude of the outbreak. However, our findings show that in-depth interviews with targeted probing for high risk situations and behaviours are essential during follow-up. These can lead to identification of further contacts and re-evaluation of initially assumed and potentially underestimated exposure risks. Interviews should also be employed to build trust between the investigators and the interviewees. Particularly in stressful situations, this will help enhance compliance and can thus be crucial for successful outbreak management. In this context, we considered the guidance provided by the CDC/WHO EVD management guideline [<xref rid="r24" ref-type="bibr">24</xref>] very helpful. For future guidelines, provision of template information material for contact persons, describing the disease as well as the rationale for control measures, would be welcome. Ideally, this material should be prepared together with experts in anthropology and psychologists with the aim to reduce fear and maximise compliance. From our experience, it should also contain information on the use of antipyretics. These were commonly used to treat the common cold by contact persons in the outbreak reported here, but can blur the onset of disease, and through prolonged inhibition of platelet aggregation may turn out to be detrimental in case of severe LF.</p><p>This investigation documents a considerable LASV exposure risk through contact to an autopsied corpse. In current guidelines reviewed in this investigation, the classification of exposure risk emerging from corpses is heterogeneous &#x02013; as high risk [<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>], medium risk [<xref rid="r26" ref-type="bibr">26</xref>], while not being explicitly mentioned in others [<xref rid="r25" ref-type="bibr">25</xref>,<xref rid="r30" ref-type="bibr">30</xref>] &#x02013; indicating the need for future harmonisation. Death from LF/VHF is the result of endothelial damage, capillary leak, shock, and multi-organ failure. Thus, corpses of patients that died of LF/VHF are likely to secrete fluids from edematous tissues, irrespective of the level of decomposition or whether they had undergone autopsy or not. This is particularly true in case of intensified volume therapy, fluid-overload, and advanced decomposition of the corpse &#x02013; the latter of which was severe in our case. As the contact to corpses is thus associated with a high risk of being exposed to infectious bodily fluids, it would be helpful that harmonised guidelines classify contact to corpses of confirmed/suspected LF/VHF cases without full personal protective equipment, as high risk exposure at any rate.</p><p>During this outbreak investigation, the assessment of symptoms consistent with LF was complicated by the concurrent peak of the influenza season. To limit psychological stress for the affected contacts and their families, we had to sensibly adapt the threshold triggering enhanced control measures, particularly isolation and quarantine. Human case reports have measured detectable viraemia in blood on day 3 of symptom onset, whereas earliest detection of LASV in urine was not until 6&#x02013;22 days after developing symptoms [<xref rid="r31" ref-type="bibr">31</xref>,<xref rid="r32" ref-type="bibr">32</xref>]. Viraemia and infectivity correlate with severity of symptoms [<xref rid="r32" ref-type="bibr">32</xref>]. Hence, a patient without severe symptoms is unlikely to be infectious through casual contact, particularly within the first 4 days of infection. The common cold typically lasts for a week, but shows no progression past day 3 of onset. We therefore decided to closely monitor all low risk contacts (III) that developed influenza-like symptoms, but no additional measures were enforced unless either a 4-day progression or more severe symptoms (including fever) occurred. For contacts with a high to medium exposure risk (I-II), any symptoms consistent with LF &#x02013; even in absence of fever - triggered additional measures. Future guidelines may follow this example and employ a comprehensive operationalisation of how and when VHF-compatible symptoms/symptom progression trigger(s) control measures, with the goal to offer treatment as early as possible to those with a significant exposure risk, while reducing unnecessary stress for the involved parties. Ideally, future recommendations would also elaborate on the anatomical location(s) for temperature measurement that the fever threshold applies to.</p><p>In summary, our report provides lessons learned that can be employed to improve the response to imported VHF cases. Complemented by the strengths identified through a comparison of relevant guidelines, this experience may be reflected in harmonised European recommendations for VHF outbreak management. In particular, we suggest classifying the exposure risk attributable to corpses of individuals that had died of a VHF as high. As part of VHF preparedness in industrialised countries, more practical training of field epidemiologists in interviewing contacts and applying available tools for the classification of communal VHF exposure is needed.</p></sec></body><back><ack><title>Acknowledgements</title><p>We would like to express our sincere thanks to Markus Lang, Harald Schirmer, Ute R&#x000f6;&#x000df;ler, Eva-Maria Wohlrab, Marco K&#x000fc;mpel, and Jennifer Mayer of the Local Health Department in Alzey for their work and support during the outbreak. We are grateful to all members of the Competence Network for Highly Pathogenic Agents, Frankfurt, as well as the team of the Institute of Virology, University of Marburg, for their advice during the outbreak. We are particularly indebted to Christian Winter and Katharina Alpers, Robert Koch Institute, Berlin, for critically reviewing the manuscript.</p></ack><notes><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold> None declared.</p></fn><fn fn-type="con"><p><bold>Authors&#x02019; contributions:</bold> GS, MG, LE, FB, PZ, MV, SB, KJ have conducted the outbreak investigation. LE, MG, and PZ have conducted the literature review. LE and PZ have drafted the manuscript. MG, FB, GS, MV, SB and KJ have reviewed and substantially contributed to the manuscript. All authors have read and approved the final manuscript.</p></fn></fn-group></notes><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="web">World Health Organization (WHO). Emergencies preparedness, response. Lassa Fever &#x02013; Germany. Disease outbreak news. Geneva: WHO; 23 Mar 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en">http://www.who.int/csr/don/23-march-2016-lassa-fever-germany/en</ext-link>
</mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="web">World Health Organization (WHO). Emergencies preparedness, response. Lassa Fever &#x02013; Togo. Disease outbreak news. Geneva: WHO; 23 Mar 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/23-march-2016-lassa-fever-togo/en/">http://www.who.int/csr/don/23-march-2016-lassa-fever-togo/en/</ext-link>
</mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>C</given-names></name><name><surname>Kochanek</surname><given-names>M</given-names></name><name><surname>Abdulla</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>B&#x000f6;ll</surname><given-names>B</given-names></name><name><surname>Bunte</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016.</article-title>
<source>Euro Surveill</source>. <year>2017</year>;<volume>22</volume>(<issue>39</issue>). <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.39.17-00088</pub-id>
</mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="web">Centers for Disease Control and Prevention (CDC). Lassa Fever. 2017. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vhf/lassa/index">https://www.cdc.gov/vhf/lassa/index</ext-link>
</mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yun</surname><given-names>NE</given-names></name><name><surname>Walker</surname><given-names>DH</given-names></name></person-group>
<article-title>Pathogenesis of Lassa fever.</article-title>
<source>Viruses</source>. <year>2012</year>;<volume>4</volume>(<issue>10</issue>):<fpage>2031</fpage>-<lpage>48</lpage>. <pub-id pub-id-type="doi">10.3390/v4102031</pub-id>
<?supplied-pmid 23202452?><pub-id pub-id-type="pmid">23202452</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCormick</surname><given-names>JB</given-names></name><name><surname>King</surname><given-names>IJ</given-names></name><name><surname>Webb</surname><given-names>PA</given-names></name><name><surname>Scribner</surname><given-names>CL</given-names></name><name><surname>Craven</surname><given-names>RB</given-names></name><name><surname>Johnson</surname><given-names>KM</given-names></name><etal/></person-group>
<article-title>Lassa fever. Effective therapy with ribavirin.</article-title>
<source>N Engl J Med</source>. <year>1986</year>;<volume>314</volume>(<issue>1</issue>):<fpage>20</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198601023140104</pub-id>
<?supplied-pmid 3940312?><pub-id pub-id-type="pmid">3940312</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bausch</surname><given-names>DG</given-names></name><name><surname>Hadi</surname><given-names>CM</given-names></name><name><surname>Khan</surname><given-names>SH</given-names></name><name><surname>Lertora</surname><given-names>JJ</given-names></name></person-group>
<article-title>Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.</article-title>
<source>Clin Infect Dis</source>. <year>2010</year>;<volume>51</volume>(<issue>12</issue>):<fpage>1435</fpage>-<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1086/657315</pub-id>
<?supplied-pmid 21058912?><pub-id pub-id-type="pmid">21058912</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asogun</surname><given-names>DA</given-names></name><name><surname>Adomeh</surname><given-names>DI</given-names></name><name><surname>Ehimuan</surname><given-names>J</given-names></name><name><surname>Odia</surname><given-names>I</given-names></name><name><surname>Hass</surname><given-names>M</given-names></name><name><surname>Gabriel</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation.</article-title>
<source>PLoS Negl Trop Dis</source>. <year>2012</year>;<volume>6</volume>(<issue>9</issue>):<fpage>e1839</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001839</pub-id>
<?supplied-pmid 23029594?><pub-id pub-id-type="pmid">23029594</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="web">Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, Bah A, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis. 2001;1(4):269-81. <pub-id pub-id-type="doi">10.1089/15303660160025903</pub-id>
<?supplied-pmid 12653127?><pub-id pub-id-type="pmid">12653127</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mylne</surname><given-names>AQ</given-names></name><name><surname>Pigott</surname><given-names>DM</given-names></name><name><surname>Longbottom</surname><given-names>J</given-names></name><name><surname>Shearer</surname><given-names>F</given-names></name><name><surname>Duda</surname><given-names>KA</given-names></name><name><surname>Messina</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>Mapping the zoonotic niche of Lassa fever in Africa.</article-title>
<source>Trans R Soc Trop Med Hyg</source>. <year>2015</year>;<volume>109</volume>(<issue>8</issue>):<fpage>483</fpage>-<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/trstmh/trv047</pub-id>
<?supplied-pmid 26085474?><pub-id pub-id-type="pmid">26085474</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fichet-Calvet</surname><given-names>E</given-names></name><name><surname>Becker-Ziaja</surname><given-names>B</given-names></name><name><surname>Koivogui</surname><given-names>L</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S</given-names></name></person-group>
<article-title>Lassa serology in natural populations of rodents and horizontal transmission.</article-title>
<source>Vector Borne Zoonotic Dis</source>. <year>2014</year>;<volume>14</volume>(<issue>9</issue>):<fpage>665</fpage>-<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2013.1484</pub-id>
<?supplied-pmid 25229705?><pub-id pub-id-type="pmid">25229705</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fichet-Calvet</surname><given-names>E</given-names></name><name><surname>Lecompte</surname><given-names>E</given-names></name><name><surname>Koivogui</surname><given-names>L</given-names></name><name><surname>Soropogui</surname><given-names>B</given-names></name><name><surname>Dor&#x000e9;</surname><given-names>A</given-names></name><name><surname>Kourouma</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa.</article-title>
<source>Vector Borne Zoonotic Dis</source>. <year>2007</year>;<volume>7</volume>(<issue>2</issue>):<fpage>119</fpage>-<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1089/vbz.2006.0520</pub-id>
<?supplied-pmid 17627428?><pub-id pub-id-type="pmid">17627428</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sogoba</surname><given-names>N</given-names></name><name><surname>Rosenke</surname><given-names>K</given-names></name><name><surname>Adjemian</surname><given-names>J</given-names></name><name><surname>Diawara</surname><given-names>SI</given-names></name><name><surname>Maiga</surname><given-names>O</given-names></name><name><surname>Keita</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.</article-title>
<source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume>(<issue>4</issue>):<fpage>657</fpage>-<lpage>63</lpage>. <pub-id pub-id-type="doi">10.3201/eid2204.151814</pub-id>
<?supplied-pmid 26981786?><pub-id pub-id-type="pmid">26981786</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klempa</surname><given-names>B</given-names></name><name><surname>Koulemou</surname><given-names>K</given-names></name><name><surname>Auste</surname><given-names>B</given-names></name><name><surname>Emmerich</surname><given-names>P</given-names></name><name><surname>Thom&#x000e9;-Bolduan</surname><given-names>C</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa.</article-title>
<source>Trop Med Int Health</source>. <year>2013</year>;<volume>18</volume>(<issue>3</issue>):<fpage>366</fpage>-<lpage>71</lpage>.
<?supplied-pmid 23279760?><pub-id pub-id-type="pmid">23279760</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ajayi</surname><given-names>NA</given-names></name><name><surname>Nwigwe</surname><given-names>CG</given-names></name><name><surname>Azuogu</surname><given-names>BN</given-names></name><name><surname>Onyire</surname><given-names>BN</given-names></name><name><surname>Nwonwu</surname><given-names>EU</given-names></name><name><surname>Ogbonnaya</surname><given-names>LU</given-names></name><etal/></person-group>
<article-title>Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012).</article-title>
<source>Int J Infect Dis</source>. <year>2013</year>;<volume>17</volume>(<issue>11</issue>):<fpage>e1011</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.05.015</pub-id>
<?supplied-pmid 23871405?><pub-id pub-id-type="pmid">23871405</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lo Iacono</surname><given-names>G</given-names></name><name><surname>Cunningham</surname><given-names>AA</given-names></name><name><surname>Fichet-Calvet</surname><given-names>E</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name><name><surname>Grant</surname><given-names>DS</given-names></name><name><surname>Khan</surname><given-names>SH</given-names></name><etal/></person-group>
<article-title>Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of lassa fever.</article-title>
<source>PLoS Negl Trop Dis</source>. <year>2015</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e3398</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0003398</pub-id>
<?supplied-pmid 25569707?><pub-id pub-id-type="pmid">25569707</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amorosa</surname><given-names>V</given-names></name><name><surname>MacNeil</surname><given-names>A</given-names></name><name><surname>McConnell</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Dillon</surname><given-names>KE</given-names></name><name><surname>Hamilton</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Imported Lassa fever, Pennsylvania, USA, 2010.</article-title>
<source>Emerg Infect Dis</source>. <year>2010</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1598</fpage>-<lpage>600</lpage>. <pub-id pub-id-type="doi">10.3201/eid1610.100774</pub-id>
<?supplied-pmid 20875288?><pub-id pub-id-type="pmid">20875288</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atkin</surname><given-names>S</given-names></name><name><surname>Anaraki</surname><given-names>S</given-names></name><name><surname>Gothard</surname><given-names>P</given-names></name><name><surname>Walsh</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Gopal</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The first case of Lassa fever imported from Mali to the United Kingdom, February 2009.</article-title>
<source>Euro Surveill</source>. <year>2009</year>;<volume>14</volume>(<issue>10</issue>):<fpage>19145</fpage>.
<?supplied-pmid 19317988?><pub-id pub-id-type="pmid">19317988</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>AW</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><name><surname>Mahmoud</surname><given-names>AA</given-names></name><name><surname>Pain</surname><given-names>AK</given-names></name><name><surname>Morris</surname><given-names>CA</given-names></name></person-group>
<article-title>Lassa fever in Britain: an imported case.</article-title>
<source>BMJ</source>. <year>1973</year>;<volume>3</volume>(<issue>5881</issue>):<fpage>616</fpage>-<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.3.5881.616</pub-id>
<?supplied-pmid 4755184?><pub-id pub-id-type="pmid">4755184</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galbraith</surname><given-names>NS</given-names></name><name><surname>Berrie</surname><given-names>JR</given-names></name><name><surname>Forbes</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>S</given-names></name></person-group>
<article-title>Public health aspects of viral haemorrhagic fevers in Britain.</article-title>
<source>R Soc Health J</source>. <year>1978</year>;<volume>98</volume>(<issue>4</issue>):<fpage>152</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1177/146642407809800407</pub-id>
<?supplied-pmid 567824?><pub-id pub-id-type="pmid">567824</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haas</surname><given-names>WH</given-names></name><name><surname>Breuer</surname><given-names>T</given-names></name><name><surname>Pfaff</surname><given-names>G</given-names></name><name><surname>Schmitz</surname><given-names>H</given-names></name><name><surname>K&#x000f6;hler</surname><given-names>P</given-names></name><name><surname>Asper</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Imported Lassa fever in Germany: surveillance and management of contact persons.</article-title>
<source>Clin Infect Dis</source>. <year>2003</year>;<volume>36</volume>(<issue>10</issue>):<fpage>1254</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1086/374853</pub-id>
<?supplied-pmid 12746770?><pub-id pub-id-type="pmid">12746770</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="web">Koch-Institute R. (RKI). Framework Ebola Virus Disease. BerlinL RKI; 24 Mar 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.rki.de/EN/Content/infections/epidemiology/outbreaks/Ebola_virus_disease/Framework_EVD.pdf?__blob=publicationFile">http://www.rki.de/EN/Content/infections/epidemiology/outbreaks/Ebola_virus_disease/Framework_EVD.pdf?__blob=publicationFile</ext-link>
</mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="web">European Centre for Disease Prevention and Control (ECDC). Public health management of persons having had contact with Ebola virus disease cases in the EU. Stockholm: ECDC; 7 Nov 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/ebola-public-health-contact-management-update-10-November.pdf">https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/ebola-public-health-contact-management-update-10-November.pdf</ext-link>
</mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="web">World Health Organization/Centers for Disease Control and Prevention (WHO/CDC). Implementation and management of contact tracing for Ebola virus disease.Geneva: WHO; Sep 2015. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/185258/1/WHO_EVD_Guidance_Contact_15.1_eng.pdf">http://apps.who.int/iris/bitstream/10665/185258/1/WHO_EVD_Guidance_Contact_15.1_eng.pdf</ext-link>
</mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="web">Public Health England (PHE). Public health recommendations for asymptomatic contacts of an Ebola case in the UK. London: PHE; 9 Feb 2015. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/402483/Public_health_recommendations_for_asymptomatic_contacts_of_an_Ebola_case.pdf">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/402483/Public_health_recommendations_for_asymptomatic_contacts_of_an_Ebola_case.pdf</ext-link>
</mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fock</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Wirtz</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>D</given-names></name><name><surname>Fell</surname><given-names>G</given-names></name><name><surname>Bussmann</surname><given-names>H</given-names></name></person-group>
<comment>(Skeleton framework concept for defence against risks in unusual epidemics: steps by public health offices)</comment>. <source>Gesundheitswesen</source>. <year>2001</year>;<volume>63</volume>(<issue>11</issue>):<fpage>695</fpage>-<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1055/s-2001-18412</pub-id>
<?supplied-pmid 11713701?><pub-id pub-id-type="pmid">11713701</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wolff</surname><given-names>S</given-names></name><name><surname>Schultze</surname><given-names>T</given-names></name><name><surname>Fehling</surname><given-names>SK</given-names></name><name><surname>Mengel</surname><given-names>JP</given-names></name><name><surname>Kann</surname><given-names>G</given-names></name><name><surname>Wolf</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany.</article-title>
<source>Genome Announc</source>. <year>2016</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e00938</fpage>-<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/genomeA.00938-16</pub-id>
<?supplied-pmid 27660771?><pub-id pub-id-type="pmid">27660771</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="web">Spiegel-Online. [Lassa patient in Frankfurt. All signs of severe infection]. Hamburg: Spiegel-Online; 17 Mar 2016. German. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.spiegel.de/gesundheit/diagnose/frankfurt-lassa-patient-schwer-krank-a-1082858.html">http://www.spiegel.de/gesundheit/diagnose/frankfurt-lassa-patient-schwer-krank-a-1082858.html</ext-link>
</mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="web">Allgemeine A. Lassa-Patient ist in einem sehr schlechtem Zustand. [Lassa patient is in a very bad condition]. Augsburger Zeitung, 18. Mar 2016. German. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.augsburger-allgemeine.de/wissenschaft/Lassa-Patient-ist-in-einem-sehr-schlechtem-Zustand-id37260962.html">http://www.augsburger-allgemeine.de/wissenschaft/Lassa-Patient-ist-in-einem-sehr-schlechtem-Zustand-id37260962.html</ext-link>
</mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="web">Advisory Committee on Dangerous Pathogens. Management of Hazard Group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence. London: Department of Health; Nov 2015. Available from: <ext-link ext-link-type="uri" xlink:href="https://naru.org.uk/wp-content/uploads/2015/11/VHF_guidance_updated_7_Sept_15.pdf">https://naru.org.uk/wp-content/uploads/2015/11/VHF_guidance_updated_7_Sept_15.pdf</ext-link>
</mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emond</surname><given-names>RT</given-names></name><name><surname>Bannister</surname><given-names>B</given-names></name><name><surname>Lloyd</surname><given-names>G</given-names></name><name><surname>Southee</surname><given-names>TJ</given-names></name><name><surname>Bowen</surname><given-names>ET</given-names></name></person-group>
<article-title>A case of Lassa fever: clinical and virological findings.</article-title>
<source>Br Med J (Clin Res Ed)</source>. <year>1982</year>;<volume>285</volume>(<issue>6347</issue>):<fpage>1001</fpage>-<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.285.6347.1001</pub-id>
<?supplied-pmid 6812716?><pub-id pub-id-type="pmid">6812716</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCormick</surname><given-names>JB</given-names></name><name><surname>Fisher-Hoch</surname><given-names>SP</given-names></name></person-group>
<article-title>Lassa fever.</article-title>
<source>Curr Top Microbiol Immunol</source>. <year>2002</year>;<volume>262</volume>:<fpage>75</fpage>-<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-642-56029-3_4</pub-id>
<?supplied-pmid 11987809?><pub-id pub-id-type="pmid">11987809</pub-id></mixed-citation></ref></ref-list></back></article>